RxDoctor Payments Data

Daphne Evans, MD

Internal Medicine · New Haven, CTNPI 1740342930

Payments from drug & device makers

$1,415in general payments, 2019–2025

Across 46 payments — averaging $30.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$214
  • Bridgebio Pharma, Inc.$207
  • Alnylam Pharmaceuticals Inc.$195
  • Heartflow, Inc.$177
  • GSK$78
  • Pfizer$78
  • plus $466 from 15 others

What the payments were for

  • Food & beverage$1,415100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,415 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$19,460
Medicare patients
90
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$21,935
JardianceEmpagliflozin11$20,084
Breo ElliptaFluticasone/Vilanterol15$6,083
Atorvastatin Calcium228$2,163
Levothyroxine Sodium114$1,589
Rosuvastatin Calcium154$1,370
SynthroidLevothyroxine Sodium16$1,357
Amlodipine Besylate170$1,317
Gabapentin85$1,240
Losartan Potassium124$986
Montelukast Sodium58$911
Lisinopril133$900
Escitalopram Oxalate65$851
Pravastatin Sodium66$827
Omeprazole31$672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$21,93517 claims
Boehringer IngelheimJardiance$25$20,08411 claims
GSKBreo Ellipta$78$6,08315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →